Compare ATAI & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAI | STAA |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2025 | 1995 |
| Metric | ATAI | STAA |
|---|---|---|
| Price | $4.05 | $28.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $15.88 | ★ $22.81 |
| AVG Volume (30 Days) | ★ 5.3M | 643.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | $4,089,000.00 | ★ $239,442,000.00 |
| Revenue This Year | N/A | $30.82 |
| Revenue Next Year | N/A | $8.41 |
| P/E Ratio | ★ N/A | $291.20 |
| Revenue Growth | ★ 1227.60 | N/A |
| 52 Week Low | $2.00 | $15.59 |
| 52 Week High | $6.73 | $35.87 |
| Indicator | ATAI | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 48.06 |
| Support Level | $3.47 | $28.10 |
| Resistance Level | $4.20 | $31.05 |
| Average True Range (ATR) | 0.31 | 1.00 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 31.20 | 25.66 |
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.